SELVAS Healthcare, Inc. (KOSDAQ:208370)
South Korea · Delayed Price · Currency is KRW 4,250.00
+60.00 (1.43%)
At close: Apr 3, 2026
SELVAS Healthcare Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 30,825 | 31,702 | 29,813 | 27,686 | 29,089 |
Other Revenue | - | -0 | -0 | -0 | -0 |
| 30,825 | 31,702 | 29,813 | 27,686 | 29,089 | |
Revenue Growth (YoY) | -2.77% | 6.34% | 7.68% | -4.83% | 37.52% |
Cost of Revenue | 15,826 | 15,141 | 14,163 | 13,701 | 15,236 |
Gross Profit | 14,998 | 16,561 | 15,650 | 13,985 | 13,853 |
Selling, General & Admin | 9,548 | 9,634 | 8,572 | 8,009 | 7,358 |
Research & Development | 3,675 | 3,161 | 3,113 | 2,798 | 2,335 |
Amortization of Goodwill & Intangibles | 118.42 | 171.85 | 198.22 | 181.25 | 189.18 |
Other Operating Expenses | - | - | - | 69.31 | 52.91 |
Operating Expenses | 15,160 | 13,287 | 12,301 | 11,498 | 10,437 |
Operating Income | -161.56 | 3,275 | 3,349 | 2,486 | 3,416 |
Interest Expense | -89.73 | -236.17 | -227.23 | -511.12 | -639.5 |
Interest & Investment Income | 653.46 | 771.93 | 466.57 | 129.93 | 95.62 |
Earnings From Equity Investments | -37.29 | -200.83 | - | - | - |
Currency Exchange Gain (Loss) | -214.58 | 1,189 | 59.29 | 372.57 | 311.19 |
Other Non Operating Income (Expenses) | 29.93 | 125.04 | 122.67 | 920.3 | 57.9 |
EBT Excluding Unusual Items | 180.22 | 4,924 | 3,770 | 3,398 | 3,241 |
Gain (Loss) on Sale of Investments | 4,685 | -1,638 | 233.99 | 19.33 | 118.05 |
Gain (Loss) on Sale of Assets | - | 13.26 | -146.44 | 3.61 | 5.08 |
Asset Writedown | -12.6 | - | - | -206.46 | -827.25 |
Other Unusual Items | - | - | - | -362.69 | - |
Pretax Income | 4,852 | 3,299 | 3,858 | 2,852 | 2,537 |
Income Tax Expense | 963.15 | 146.94 | -1,312 | 39.05 | 65.18 |
Net Income | 3,889 | 3,152 | 5,170 | 2,813 | 2,472 |
Net Income to Common | 3,889 | 3,152 | 5,170 | 2,813 | 2,472 |
Net Income Growth | 23.39% | -39.03% | 83.79% | 13.81% | 225.77% |
Shares Outstanding (Basic) | 26 | 26 | 24 | 22 | 22 |
Shares Outstanding (Diluted) | 26 | 26 | 24 | 24 | 22 |
Shares Change (YoY) | -0.31% | 6.86% | 2.31% | 9.11% | 0.02% |
EPS (Basic) | 151.00 | 123.00 | 215.14 | 126.14 | 114.12 |
EPS (Diluted) | 151.00 | 122.00 | 214.00 | 94.38 | 114.00 |
EPS Growth | 23.77% | -42.99% | 126.75% | -17.21% | 225.71% |
Free Cash Flow | -552.04 | 3,783 | 3,112 | -301.51 | 2,557 |
Free Cash Flow Per Share | -21.43 | 146.44 | 128.72 | -12.76 | 118.08 |
Gross Margin | 48.66% | 52.24% | 52.50% | 50.51% | 47.62% |
Operating Margin | -0.52% | 10.33% | 11.23% | 8.98% | 11.74% |
Profit Margin | 12.62% | 9.94% | 17.34% | 10.16% | 8.50% |
Free Cash Flow Margin | -1.79% | 11.93% | 10.44% | -1.09% | 8.79% |
EBITDA | 772.81 | 4,323 | 4,360 | 3,585 | 4,998 |
EBITDA Margin | 2.51% | 13.64% | 14.62% | 12.95% | 17.18% |
D&A For EBITDA | 934.37 | 1,048 | 1,011 | 1,099 | 1,582 |
EBIT | -161.56 | 3,275 | 3,349 | 2,486 | 3,416 |
EBIT Margin | -0.52% | 10.33% | 11.23% | 8.98% | 11.74% |
Effective Tax Rate | 19.85% | 4.45% | - | 1.37% | 2.57% |
Advertising Expenses | 428.58 | 390.55 | 283.96 | 361.05 | 89.95 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.